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STRUCTURE AND FUNCTION
OF THE DROSOPHILA EYE
The eye of the fruit fly Drosophila melanogaster is a
complex structure formed by a specific structural unit –
the ommatidium, the corneal lens of which has the form
of a convex hexagon facet. The faceted eye of the fruit fly
is formed by 700 to 800 ommatidia with a transverse size
of about 15 µm; the overall size of the compound eye is
400 µm [1]. Ommatidia have their own lightrefracting
(dioptric), photoinsulative, and photosensitive compo
nents (Fig. 1).
The lightrefracting apparatus of an ommatidium is
formed by the transparent corneal lens and the crystalline
cone (Fig. 1). Analysis of the cornea with atomic force
and electron microscopy has revealed that facets are cov
ered with a network of transparent cuticular nipples with
the height of 30 nm and width of about 250 nm [2, 3].
These nanostructures facilitate penetration of visible light
with λ = 320700 nm from the air into the denser medi
um of the eye [4, 5] and help cleanse the eye through the
waterrepellent function (the “lotus leaf” effect) [5]. The
corneal lens operates in conjunction with the directly
adjacent crystalline cone. The latter is a transparent body
formed by four cone cells.
The photoinsulative apparatus of an ommatidium
consists of pigment cells containing pigment granules pos
sessing lightshielding function. Pigment cells increase the
sensitivity of ommatidia and insulate rhabdomeres (light
sensitive photoreceptor membranes, see below) from side
ways illumination. Each ommatidium contains two pri
mary pigment cells, while the secondary and the tertiary
pigment cells are shared between two and three neighbor
ing ommatidia, respectively: the secondary pigment cells
are located along the edges of the hexagonal ommatidium,
and tertiary – in its alternating vertices (Fig. 1).
The photoreceptor function of an ommatidium is
provided by eight lightsensitive or reticulum cells (pho
toreceptors), each of which carries a rhabdomere – a
dense, initially apical plasma membrane formation that is
responsible for light detection and generation of nerve
impulses. Each rhabdomere contains about 60,000
microvilli filled with the visual pigment and having a diam
eter of 50 nm. Rhabdomeres of the outer photoreceptors
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R1R6 ensure formation of visual images and penetrate
the entire thickness of the retina. These rhabdomeres con
tain the protein opsin 1 (Rh1) capable of absorbing light in
the visible range (absorption maximum – 478 nm).
Between the outer rhabdomeres there are rhabdomeres of
the central photoreceptors R7 and R8, each occupying
half the thickness of the retina (Fig. 1). Opsin expression in
these cells is strictly coordinated. On the basis of their
photoreflecting properties, two types of ommatidia are
distinguished: pale and yellow [6]. Yellow ommatidia rep
resent 65% of the total number of ommatidia and contain
UVsensitive R7cells (absorption maximum – 375 nm)
and R8cells with absorption in the green spectral region
(absorption maximum – 508 nm). R7 expresses opsin 4,
and R8 expresses opsin 6. Pale ommatidia contain UV
sensitive cells R7 (absorption maximum – 345 nm) and R8
sensitive in the blue range (absorption maximum –
437 nm). R7 of the pale ommatidia express opsin 3, and
the R8 cell expresses opsin 5 [7, 8]. There is also a special
ized class of ommatidia along the dorsal (upper) edge of
the eye (dorsal rim) that are sensitive to polarized light,
and opsin 3 is present in both R7 and R8 cells of these
ommatidia [9].
In addition to the visual function, the insect eye also
has a tactile capacity due to the presence of mechanosen
sitive bristles arranged in alternating hexagon vertices of
the ommatidia (Fig. 1) and outstanding by 1520 µm
above the surface of the eye.
STAGES OF EYE DEVELOPMENT
IN DROSOPHILA
The development of flies occurs with complete
metamorphosis (the holometabolic life cycle). Larvae
have imaginal discs – groups of cells from which struc
tures of the imago (adult) are formed at the pupal stage
while larval tissues are destroyed. The eye, along with the
antenna and the adjacent areas of the cuticle, is formed
from the eyeantennal imaginal disc. This disc is formed
from a part of the cellular blastoderm, consisting of
approximately 20 cells, and is located in the dorsolateral
ectoderm. In the early stages, the eyeantennal imaginal
disc distinguishes itself from the surrounding tissue by
expression of proteins Twin of eyeless (Toy) and Eyeless
(Ey), homologs of the transcription factor Pax6, which in
mammals is also expressed at the earliest stages of eye
formation. Ectopic expression of Ey and Pax6 in flies can
cause formation of eyes in new, unusual places [10, 11].
Up to the third instar larval stage the disc simply
increases in size due to cell proliferation. Thus, by the end
of the first instar larval stage the disc contains about 130
cells, while by the beginning of the third – about 10,000.
This sequence of divisions is called “the first mitotic
wave” [1]. By the third instar larval stage the eyeanten
nal imaginal disc is a monolayer of actively dividing cells
of columnar epithelium. At about 70 h before pupariation
(at 20°C) sequential differentiation of eye cells begins.
The first cells to stop division are those located at the back
(posterior) position of the disc. In these cells, a change of
expression profile takes place, and they begin to transmit
a signal to neighboring cells, which, in turn, leads to ces
sation of division in them. Thus, the process sequentially
involves more new cells. The division arrest is accompa
nied by changes in the cell shape, which result from con
striction of the actin cytoskeleton, and coincides with the
transition of cells to the G1 phase of the cell cycle. Under
the microscope one can see how the front called morpho
genetic furrow (MF) sweeps from the posterior to the
anterior side of the imaginal disc (Fig. 2). MF moves
through the disc until it reaches its anterior in about
2 days [1]. The initiation of MF is divided into birth and
reincarnation. The birth is the appearance of the first
group of cells that have passed to the G1 stage of the cell
cycle. These cells trigger the whole cascade of promotion
of MF. However, the imaginal disc is a rounded structure
and, until MF reaches the middle of the disc, more and
more rows of cells on each side are being continuously
included. In each such row the furrow should be reiniti
ated. This process is called reincarnation.
Fig. 1. Structure of the ommatidium in longitudinal section (left)
and crosssections at several levels of the retinal depth (right). 1)
Corneal lens; 2) crystalline cone; 3) cone cell; 4) tertiary pigment
cells; 5) primary pigment cell; 6) secondary pigment cell; 7) bris
tle; 812) R3R7 photoreceptor cells, respectively; 13) R2 pho
toreceptor cell; 14) R8 photoreceptor cell; 15) R1 photoreceptor
cell; 16) axons; 17, 18) R7 and R8 cell rhabdomeres, respectively;
19, 20) external photoreceptor rhabdomeres.
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As described above, MF is a zone of cell division
arrest. Immediately behind MF sequential differentiation
begins (Fig. 3). First, individual cells choosing the path of
neuronal differentiation appear within the undifferentiat
ed tissue at regular distances from each other. These are
the future photoreceptors R8. They recruit four neighbor
ing cells, which also become photoreceptors: R2, R3, R4,
and R5. Next R1 and R6 cells join the premature omma
tidium. The last photoreceptor cell to be specified is R7
[1]. As MF moves in space, behind it (i.e. on the posteri
or side from MF) one can see the succession of the stages
of compound eye formation described above. For conven
ience, researchers identify each stage of formation of
ommatidia behind MF as a “row”. In the front row R8
cells start to specialize, while the second row contains the
R8cells which specialized 90 min earlier. Thus, while the
precluster of five photoreceptor cells is forming in the
second row, R1 and R6 are specializing in the fifth row,
and R7 – in the seventh. By the end of the larval stage
about 26 rows of ommatidia are formed. The remaining
ones are completed within the first 10 h of pupariation
[1].
Between the third and fifth rows of ommatidia, when
R8 cells and R2R5 cells are specialized and together
constitute the ommatidial precluster, the undifferentiated
cells surrounding the photoreceptors divide again. This
division is called the second mitotic wave and serves to
increase the number of cells available for subsequent
phases of recruitment to the ommatidia [1].
Rhabdomeres of the adult ommatidium in a cross
section form an irregular trapezoid, that is, a figure that
has chirality (Fig. 1). From the anterior to the posterior
edge of the eye runs the equator – an imaginary line drawn
between mirroring ommatidia of the upper and lower
halves of the eye (Fig. 4). Ommatidial chirality is defined
by photoreceptors R3 and R4, and is formed in the imag
inal eyeantennal disc shortly after MF passes, when there
are five cells in the ommatidial precluster, and is accom
panied by rotation of the preclusters by 90° (see below, sec
tion “Frizzled/PCPSignaling Cascade in Regulation of
Ommatidial Polarity in Drosophila” of chapter “Non
canonical Frizzled/PCPSignaling Cascade”).
The last photoreceptor cell to differentiate is R7, and
it is different from the rest of the photoreceptors so that
antennal part eye part
anterior side posterior side
Fig. 2. Morphogenetic furrow (MF) in the eyeantennal disc of a
third instar larva and factors that govern its progression.
Originating at the posterior pole, MF moves towards the anterior.
Cells “behind” (on a posterior side of) MF are at different stages
of differentiation; the cells ahead of MF are undifferentiated.
Hedgehog (Hh) is synthesized by differentiating cells at the front
of MF, stimulating expression of the proneural factor Atonal
(Ato). Another target of Hh is Decapentaplegic (Dpp), which dif
fuses farther than Hh beyond MF into the undifferentiated region
to prepare cells for neuronal differentiation through repression of
Homothorax (Hth). Notch (N) is activated in the MF area
through stimulated expression of its ligand Delta under the con
trol of redundant Hh and Dppdependent signaling cascades and
promotes neuronal differentiation through suppression of repres
sors Hairy and Extra macrochaetae (Emc). Wingless (Wg) diffus
es from the head capsule to play a limiting role preventing initia
tion of ectopic MF.
MF
Fig. 3. Sequence of cell differentiation in ommatidia. Different stages of development of ommatidial preclusters are displayed, from the ear
liest (on the left, near MF) to mature. The first to emerge R8photoreceptor recruits photoreceptors R2 and R5, sending the EGFRactivat
ing Spitzligand (black arrows), which is later on used for differentiation of photoreceptors R3/R4 and cone (C) cells. R7 photoreceptor
receives a double signal: activation of the Notchreceptor by Deltaligands (open arrows) from R1 and R6 cells, and activation of the
Sevenlessreceptor by the Bossligand from the R8photoreceptor (black arrowheads). Cone cells also receive a double signal: Spitz and Delta.
The Notchsignaling cascade is additionally involved in specification of the R4photoreceptor from the R3/R4pair of initially equivalent pro
genitor cells (shown in the third ommatidial precluster).
anterior side posterior side
C
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for proper specialization it requires the simultaneous acti
vation of two types of signaling cascades [12] (see section
“The NotchCascade in Development of Photoreceptor
R7” of chapter “The NotchSignaling Cascade” and
chapter “The Receptor Tyrosine KinaseSignaling
Cascade”): the Delta signal from R1 and R6 cells on one
hand and the Boss signal from the R8 cell on the other
(Fig. 3).
When differentiation of photoreceptors is over, non
neuronal cells start to specialize. At first cone cells are
formed. After them the primary, secondary, and tertiary
pigment cells emerge. The last to differentiate are
mechanosensitive bristles, one for every three ommatidia.
After completion of cell division, cells receive a sig
nal from photoreceptors that controls their survival
through activation of the receptortyrosine kinase path
way (see section “The RTKSignaling Cascade in
Drosophila Photoreceptor Recruitment” of chapter “The
Receptor Tyrosine KinaseSignaling Cascade”). Cells
that have not received enough of this signal die. This is the
first wave of apoptosis, in which one cell dies among every
35 ommatidia. A few days later, during late stages of dif
ferentiation, the second wave of apoptosis takes place. At
this time in each ommatidium 23 cells die, and the sur
vival signal comes from cone and primary pigment cells.
Surviving cells become secondary and tertiary pigment
cells, or divide, producing mechanosensitive bristles [1].
A bristle consists of four cells, which are formed by
three divisions of a single cell precursor. Formation of
bristles of the eye has not been sufficiently investigated,
but it apparently occurs along the same rules as formation
of mechanosensitive bristles located on the fly thorax and
wings. The basis of bristle formation is the asymmetry of
divisions of cell precursors. During the first cell division,
the precursor produces the anterior and posterior daugh
ters, which differ in their content (in particular in the
presence or absence of the protein Numb). The anterior
daughter, which inherits Numb, asymmetrically divides
two more times with the formation of inner cells of sen
sory bristles (a neuron, a glial cell and a supporting cell of
the neuron membrane (sheath cell)). The posterior cell
not inheriting Numb divides once asymmetrically to form
the outer cell components of the bristle: the hair and the
shaft [13].
As will be seen below, each of the stages of eye devel
opment is strictly regulated by intracellular signaling sys
tems. Longterm studies of the Drosophila visual organ
have produced extensive knowledge explaining which sig
naling pathways are responsible for which stages of mor
phogenesis, and which kind of morphological and histo
logical disorders occur in the eye from perturbations of
the signaling mechanisms. Given the high degree of
homology and interchangeability of components of sig
naling pathways between insects and mammals, all of this
makes the developing eye of Drosophila an ideal model
system for studying the mechanisms of human signaling
proteins. The following sections describe in detail the sig
naling pathways involved both in the development of the
fruit fly’s eyes and various human pathologies.
SIGNALING PATHWAYS THAT REGULATE
EYE DEVELOPMENT IN DROSOPHILA
Signal transmission in the cell (intracellular signal
ing, cell signaling) is part of a complex system of commu
nication that governs basic cellular processes and coordi
nates the activities of the cell. The ability of cells to
respond properly to changes in their environment is the
foundation of development, tissue regeneration, immune
system, and homeostasis maintenance in general. The
process of signal transmission involves a chain of bio
chemical reactions inside the cell, based either on pro
tein–protein interactions and posttranslational modifica
tions, or on stimulation/inhibition of the production of
second messengers – low molecular weight intracellular
substances which in turn regulate the activity of protein
signal transmitters. Typically, the number of molecules
involved in cell signaling increases with the progression to
each following step of signal transmission. This process is
called amplification of the signal. Thus, one talks about
the signaling cascade that begins with a relatively weak
a
c c
b b
Fig. 4. Chirality and orientation of ommatidia in the eye of
Drosophila. The head of Drosophila is shown “enface” with the
oral apparatus (a), antennae (b), and eyes (c). Crosssections of
four ommatidia, one per each hemisphere of each eye (taken at the
level of R7photoreceptors), are schematically magnified.
Numbers indicate rhabdomeres of photoreceptors R1R7. The
crosssections reveal chirality in the arrangement of rhabdomeres
of the six outer photoreceptors: photoreceptor R3 is “pushed” out
from the group of remaining photoreceptors. The universality of
orientation of the ommatidia is also obvious: they always point
with their R3photoreceptors in the polar direction (towards the
head capsule). Chirality and orientation of ommatidia in the dor
sal half of the eye are the mirrorreflected image of the ventral half;
the eye has an imaginary line of reflection (the equator). In addi
tion, chirality and orientation of the left eye ommatidia are mirror
reflected in the right eye.
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stimulus and causes a significant response. We should add
that both positive and negative feedbacks are present in
signaling cascades, and there is a considerable overlap of
different signaling pathways. In this regard, the represen
tation of intracellular signal transduction as a simple lin
ear chain of reactions is a simplification, and more
recently studies of signaling as a network of molecular
interactions started to gain popularity [14, 15].
There are very few types of signal substances and
their receptors, and thus types of signaling pathways that
transmit them. For example, there are only five basic
types of signaling pathways that are active during early
embryogenesis [16]: (i) the Notchsignaling cascade; (ii)
the Hedgehogdependent signaling cascade; (iii) TGFβ
cascades; (iv) Wnt/Frizzledsignaling cascades, and (v)
cascades triggered by tyrosine kinase receptors. Because
these types of signaling pathways are responsible for early
stages of development of multicellular animals, their
activity in adulthood is limited. Since improper activation
of these signaling pathways promotes malignant transfor
mation, development of substances that affect these sig
naling pathways is an obvious and actively pursued direc
tion for anticancer drug development [17]. This makes
the study of intracellular signal transduction pathways
that are active in ontogenesis not only important from the
standpoint of fundamental biology of development, but
also medically significant. Drosophila eye development
reiteratively uses all these signaling pathways, thus pro
viding researchers with a very promising model system.
THE NOTCHSIGNALING CASCADE
Notch is a receptor with one transmembrane region,
Nterminal extracellular, and Cterminal intracellular
domains and initiates the intracellular signaling that is
one of the most widely used pathways in multicellular
animal development [18, 19] (Fig. 5). Notch regulates
cell fate specification during development by increasing
the molecular differences between cells. The Nterminal
portion of the Notch receptor in Drosophila consists of
36 EGFlike repeats and three LNR (lin12/Notch
repeat) repeats [20]. EGFlike repeats number 11 and 12
are responsible for interaction with ligands [21]. The
extracellular part of Notch also contains the het
erodimerization domain. On the intracellular side Notch
contains the RAMlike domain, ankyrin repeats, the
transcriptional domain, and the PESTdomain, which
regulates the stability of the receptor [22]. In the endo
plasmic reticulum (ER) EGFlike repeats of Notch are
glycosylated by the Oglycosyltransferase Rumi and fuco
sylated by the Ofucosyltransferase, and then Nacetyl
glucosamine is added to the fucose by the Fringe enzyme
activity in the Golgi apparatus [23]. The first proteolytic
cleavage (S1) of Notch also takes place in the Golgi; this
cleavage occurs within the heterodimerization domain
before the transmembrane region and is performed by the
protease Furin. This completes the processing reactions,
and the readytouse receptor, two parts of which are
joined by noncovalent bonds within the heterodimeriza
tion domain, is delivered to the plasma membrane [24,
25].
Intracellular signaling triggered by the receptor
Notch has several key features that distinguish it from
other types of signaling cascades. The first such difference
is that the ligands for Notch are not secreted molecules,
but instead belong to the DSL (Delta, Serrate, Lag2)
family of transmembrane proteins. This feature implies
that activation of the Notchdependent signaling occurs
through a direct contact of two neighboring cells. Binding
of a DSLligand triggers proteolytic cleavages of the
Notchreceptor, called S2 and S3. The S2cleavage is
performed by metalloproteases of the ADAM/TACE/
Kuzbanian family and removes the extracellular portion
of the receptor [26]. The subsequent S3cleavage of the
molecule occurs in the lipid membrane layer by the action
of γsecretase – a complex of proteins including prese
Fig. 5. Notchdependent signaling cascade: the stages of matura
tion and intracellular signaling by the Notchreceptor. 1, 2)
EGFlike repeats of Notch are glycosylated by the Oglycosyl
transferase Rumi and fucosylated by the Ofucosyltransferase in
the endoplasmic reticulum; 3) Nacetylglucosamine is added to
fucose by the Fringe enzyme activity in the Golgi apparatus; 4)
the first proteolytic cleavage (S1) of Notch at the site located in
the heterodimerization region in front of the transmembrane
domain is performed by the Furin protease in the Golgi appara
tus; 5) binding of a DSLligand (transmembrane protein of the
neighboring cell) triggers Notch proteolytic S2 cleavage by met
alloprotease of the ADAM/TACE/Kuzbanian family that
removes the extracellular portion of the receptor; 6) γsecretase
cleaves the intracellular portion of Notch (NICD) which translo
cates to the nucleus. In the nucleus NICD binds the transcription
factor Su(H) and the coactivator Mam, triggering transcription
of target genes.
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nilin, nicastrin, Aph1, and Pen2, which is also responsi
ble for a similar cleavage of the amyloid precursor protein
(APP) and is thus associated with development of
Alzheimer’s disease [27]. The S3cleavage releases the
cytoplasmic domain of the activated Notchreceptor
(NICD). Translocating into the nucleus, NICD interacts
with the transcription factor Su(H) [28]. Binding of
NICD alters the properties of Su(H), transforming it
from a transcriptional suppressor to an activator, directly
displacing a corepressor (deacetylase) and binding the
coactivatory proteins of the Mam family. This leads to an
increase in transcriptional activity and is associated with
recruiting the coactivatory histone acetyltransferase
[29]. The best described target genes of this signaling cas
cade are transcription repressors of the HES/HEY family
related to the basic helixloophelix family proteins.
Furthermore, among the target genes are regulators of
cell proliferation Myc and cyclinD, as well as compo
nents of other signaling pathways such as EGFR [29].
The second fundamental difference of the Notch
dependent signaling pathway from most other signaling
pathways is the apparent lack of amplification of the sig
nal in its intracellular transmission. Indeed, one molecule
of a DSLligand binds one molecule of the Notchrecep
tor, the intracellular portion of which goes after S2/S3
proteolysis into the nucleus and forms a stoichiometric
complex with Su(H) and Mam, which stimulates tran
scription of target genes. However, amplification of the
signal is “hidden” in the positive feedback triggered by
transcription. The fact is that among the target genes of
the Notchcascade are the Notch gene itself and also
genes that stimulate the activity of the Notch pathway
[29, 30], whereas transcription of DSLligands is indi
rectly (through downregulation of the transcription factor
achaete/scute) repressed by Notch signaling [31]. We
remind that DSLligands are transmembrane proteins,
which provide activation of Notch signaling by direct
intercellular contacts. If the two contacting cells carry on
their surface both DSLligands and Notchreceptors,
activation of the Notchcascade is stimulated in both cells
(this is achieved through transactivation; it is appropriate
to note that cisactivation of Notch does not take place;
moreover, there exists cisinhibition of the Notchrecep
tor by DSLligands located on the same membrane [32,
33]). However, over time, due to the feedback in the form
of stimulated production of Notch and the suppressed
synthesis of the ligand, one of the cells, which had initial
ly a slight advantage in the number of Notchreceptors on
their surface or their activity, begins to “overplay” the
other cell in the level of activation of the cascade. After
several rounds of activation of this signaling pathway and
the regulated transcription, one of the two initially simi
lar cells is left with a significant level of expression of the
Notchreceptor and low expression of DSLligands, and
ultimately with a significant level of activation of the
Notch pathway and expression of its target genes. At the
same time, the Notchcascade of the second cell is turned
off – both because of low level expression of the receptor
and other components of the pathway, and because of
high level expression of the ligands, leading to cisinhibi
tion of small amounts of the available receptor. This phe
nomenon is called “lateral inhibition” and is used repeat
edly during development of multicellular animals, such as
selection of several neuronal precursors from a pool of
initially equivalent epithelial cells (see below) [34].
Participation of the Notchdependent signaling cas
cade in development of human pathologies. The Notch
dependent signaling pathway is involved in numerous
developmental programs both in Drosophila, which will
be described in the following sections with the example of
its eyes, and humans. Mutations in genes encoding com
ponents of this signaling cascade are the basis of a num
ber of hereditary or somatic diseases of humans. We will
discuss some examples.
Tcell acute lymphoblastic leukemia (TALL) is one
of the most common forms of leukemia, especially in
children. The role of excessive activation of the Notch
pathway in development of this cancer was initially
detected through analysis of the chromosomal transloca
tion (7;9)(q34;q34.3) in a group of patients with TALL.
This translocation, as it turned out, leads to formation of
a truncated Notch1 gene, expression of which leads to
constitutive, ligandindependent activation of the Notch
cascade [35]. Subsequent studies have revealed frequent
point mutations in the gene for Notch1, especially in
areas that encode its heterodimerization domain and
PESTdomain, which controls degradation of NICD
[36]. Activating mutations in the Notch1 heterodimeriza
tion domain stimulate ligandindependent S2receptor
cleavage, which is accompanied by S3cleavage and acti
vation of Notch, whereas mutations in the PESTdomain
improve the stability of the liberated through the S3
cleavage intracellular Notch (NICD) domain [22, 37]. In
general, activating mutations in Notch1 are found in
more than half of all cases of TALL; in approximately
1020% of cases simultaneous mutations in the het
erodimerization and PESTdomains are found, which
speaks for the synergy of these two routes of mutational
activation of Notch [22].
Cerebral autosomal dominant arteriopathy with sub
cortical infarcts and leukoencephalopathy (CADASIL
syndrome) is a dominant hereditary pathology character
ized by recurrent ischemic stroke, migraine, and demen
tia [38]. CADASILsyndrome is typically manifested at
the age of 45 and by some estimates occurs with a fre
quency of 1 case per 50,000 people [38]. Genetic studies
have revealed that mutations in Notch3 are responsible
for the syndrome [39, 40], causing addition or loss of cys
teine residues in one of the 34 EGFrepeats of the extra
cellular domain of Notch3 [41]. It is assumed that it
interferes with the normal formation of disulfide bonds in
EGFrepeats (normally three bonds per repeat) and the
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functioning of the receptor, but it has not been established
yet whether these mutations increase or decrease the
activity of Notch3 [42]. It is known that in CADASIL
syndrome extracellular parts of Notch3 accumulate on
the surface of smooth muscle cells of arterioles, presum
ably due to multimerization of the mutant form of the
receptor due to formation of incorrect intermolecular
disulfide bonds [43, 44]. This accumulation causes death
of smooth muscle cells of arterioles and as a conse
quence – loss of cerebral arteries that feed the subcortical
neurons, and death of the latter, usually accompanied by
fatality in 1520 years after the onset of symptoms [42].
Alagille syndrome is an autosomal dominant, multi
system pathology characterized by developmental defects
of the liver, heart, skeleton, and eyes, which appear in
early childhood with a frequency of approximately 1 case
per 100,000 infants. Mortality in the Alagille syndrome is
1520% and in half of the cases occurs as a result of the
heart disease (in infants), and in half liver failure due to
immaturity of bile ducts (at later stages); there is no treat
ment for this pathology [45]. In the majority (about 90%)
of cases the cause of the syndrome are lossoffunction
mutations in JAG1, encoding a ligand for Notchrecep
tors [46, 47], and in some cases (6%) – mutations in
Notch2 [48]. The dominance of Alagille syndrome is
associated with Notchdependent haploinsufficiency of
the signaling cascade: simple reduction in the number of
active ligands due to mutations in one of the two alleles of
JAG1 (or receptors due to mutations in one of the two
alleles of Notch2) leads to a decrease in activity of the
Notchcascade and developmental defects. It is worth
mentioning that homozygous mutations in the genes for
JAG1, Notch2, and other components of the Notchcas
cade are lethal during early embryogenesis.
Insufficient or, conversely, excessive activity of the
Notchdependent signaling pathway underlies many
human pathologies. We can mention pancreatic cancer,
skin and cervical cancers, spondylocostal dysostosis and
hereditary bicuspid aortic valve [42, 49, 50]. These exam
ples underscore the medical importance to study mecha
nisms of this type of intracellular signaling. Drosophila
eye provides a very convenient object for such studies, and
subsequent sections describe the role of the Notchcas
cade in regulation of various stages of development of this
organ.
The Notchpathway in early stages of eye develop
ment. Proper eye development in Drosophila depends on
a clear separation of dorsal and ventral sides of the organ
and formation of the equator between the two. These
processes are ensured by activation of the Notchcascade
at the boundary between the dorsal and ventral halves of
the growing eye. In early imaginal eyeantennal discs, the
DSLligand Delta is expressed primarily dorsally, and the
ligand Serrate – ventrally. In addition, Nacetylglu
cosamine transferase Fringe is also expressed ventrally.
Fringe modifies Notch to make it insensitive to activation
by the Serrateligand, but stimulating its activation by the
ligand Delta. As a result, Notch is activated mainly at the
border between the ventral and dorsal compartments, dis
tinguishing this border as a zone of specialized cell–cell
interactions and activation of signaling cascades. This is
necessary for the growth of the eye, as well as for estab
lishment of the equator as the region of reflection of chi
rality and orientation of ommatidia [5153]. Aberrant
Notch activity at the border zone leads to defects in the
chirality of ommatidia, while complete loss of its activity
leads to eye loss [51]. In contrast, excessive activation of
Notch produces overgrowth of the eye tissue [51].
Participation of the Notchcascade in growth of the
eyeantennal disc is determined by its role in initiation of
morphogenetic furrow (MF) on the posterior pole of the
early disc. Activation of Notch at the dorsoventral bound
ary (which coincides with a posterior pole of the early
disc) leads to expression of the transcription factor Eyg,
which in turn stimulates production of Unpaired – a lig
and that activates the Jak/STAT signaling cascade and
initiation of MF [54].
The Notchpathway is responsible for specification of
R8cells. In the process of MF progression, activation of
the Notchcascade stimulates transition of cells into the
G1 phase and expression of proneural factors atonal and
daughterless [55]. This is accomplished through Notch
dependent suppression of transcription repressors hairy
and extra macrochaetae [56]. Synthesis of proneural fac
tors by a large group of cells within MF marks their com
mitment to neuronal differentiation, and loss of Notch
activity at this stage leads to lack of induction of R8pho
toreceptors and neuronal differentiation in general [56,
57]. However, after the passage of MF, atonal expression
gradually narrows down to clusters and then to individual
cells, which become R8 photoreceptors. Loss of expres
sion of atonal in many cells of a cluster competent for
neuronal differentiation is achieved by the Notch
dependent mechanism of lateral inhibition, and decrease
in Notch activity at this stage, in contrast, leads to exces
sive differentiation of multiple R8cells [55, 58]. The
transition of cells from activating the expression of atonal
to its suppression in response to stimulation by Notch sig
naling involves a shift in the mechanism of regulation of
expression of this gene. At the stage of MF passage, aton
al transcription is determined by proteins that bind to its
3′enhancer, while at the later stages the most defining is
the 5′enhancer which is responsible in particular for the
binding of the protein atonal itself and thus for selfacti
vation of its transcription [55, 59]. And if the Notch
mediated cascade is able to stimulate expression under
the control of the 3′enhancer, the 5′enhancer, in con
trast, is inhibited by the activity of this signaling pathway
[55]. It is interesting to emphasize the importance of self
activation of the proneural gene atonal. In other examples
of the lateral inhibition, Notch can suppress other
proneural genes such as achaete/scute [31, 60], but the
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ability of such Notchrepressed genes to selfactivate
appears as a precondition for the functioning of the
mechanism of lateral inhibition. The result of Notch
activity at this stage of eye development is specification of
evenly spaced R8photoreceptor cells, each of which fur
ther recruits their future partners in the ommatidia from
the mass of undifferentiated cells.
The Notchcascade in development of photoreceptor
R7. Differentiation of photoreceptors R1R6 takes place
because of their exposure to EGF secreted by the R8
photoreceptor to build the photoreceptor cluster of nas
cent ommatidia (see section “The RTKSignaling
Cascade in Photoreceptor Recruitment in Drosophila” of
chapter “The Receptor Tyrosine KinaseSignaling
Cascade”). In contrast to these photoreceptors, R7
requires for its specification a double activation: the Ras
dependent signaling cascade and the Notchcascade. In
the absence of the latter, the R7 cellprecursor chooses
the R1R6 fate [12, 61]. Activation of the Notchcascade
in the R7precursor cells is achieved by expressing the lig
and Delta by R1 and R6 cells [12]. Curiously, these cells
also express the Notchreceptor, whereas R7 also express
es the Deltaligand. Moreover, it has been shown that
direct activation of Notch signaling in R1R6 cells turns
them into R7 [12, 61]. How do interacting R1, R6, and
R7 precursor cells determine which of the two cell fates
(R1/R6 or R7) to choose if the choice depends on the
Notchcascade, which can be activated in all three cells?
The answer is the lateral inhibition and a specific spatial
arrangement of these three interacting cells (see Fig. 3).
In an ommatidial precluster the R7cell is in a physical
contact with R1 and R6, while the latter are not in con
tact with each other. Thus, the R7cell receives approxi
mately twice more Deltasignal (from R1 and R6) than
R1 or R6 (each gets the Deltasignal only from R7). As a
result, the Notchcascade is initially stronger in the R7
precursor, which through lateral inhibition leads to a sit
uation where it is active only in R7 and is not active in
R1/R6. As in the cases described above, an important role
in Notchdependent specification of R1/R6 and R7 cells
is the cisinhibition by the ligand Delta [62].
The Notchcascade in development of mechanosensi
tive eye bristles. Let us consider another mechanism of
action of Notchdependent differentiation that occurs
during the development of mechanosensitive eye bristles.
Each bristle contains 45 cells, which are descendants of
a single cell precursor (see above). The precursor cell
divides asymmetrically in the anterior–posterior direc
tion. The asymmetry of this division manifests itself in
particular in the concentration of protein regulators of
Notch signaling Numb and Neuralized on the anterior
pole of the dividing cell and in the exclusive inheritance
of these proteins by the anterior daughter cells [6365].
Numb inhibits Notch signaling in the anterior [64], while
Neuralized increases the ability of the ligand Delta from
the anterior cell to activate Notch in its posterior neigh
bor [65]. As a result, the Notchcascade is activated only
in the posterior cell, which is responsible for the develop
ment of external cell components of the bristle: the hair
and the socket. The anterior cell, in turn, produces inner
cells (the neuron, the shaft cell and the glial cell; the lat
ter often dies at later stages [66]).
HEDGEHOGDEPENDENT SIGNAL
TRANSDUCTION
Hedgehog (Hh) is a secreted protein first described
in Drosophila, where Hh was identified as one of the seg
ment polarity genes [67]. Mutations in this gene lead to
defects in early embryogenesis with formation of a “lawn”
of denticles on the ventral side of the embryo, hence the
name of this protein “hedgehog”.
Hh is synthesized in the ER as a precursor with a
molecular mass of 45 kDa, and completes its processing
in the Golgi apparatus. Hh acquires characteristics of a
secretory molecule through intramolecular autoproteoly
sis and lipid modification of the precursor protein.
Autoproteolysis is catalyzed by the Cterminal domain of
the protein by a mechanism resembling the protein splic
ing of inteins: the cysteine residue in the conservative
Gly′CysPhe string of the proteolysis site plays the role of
a nucleophile in hydrolysis of the peptide bond.
Cholesterol, serving as an electron donor for this reac
tion, is recruited by the sterolbinding motif of the Cter
minal domain of the precursor protein. The result of this
processing is a biologically active HhN peptide with the
mass of 19 kDa, esterified at the Cterminus with choles
terol [6870] (Fig. 6).
Biologically active Hh has another lipid modifica
tion: palmitoylation on the Nterminus, catalyzed by the
acyltransferase Skinny Hedgehog [71]. Such double lipi
dation is necessary for proper secretion and activity of
Hh, but brings about some restrictions both to the process
of release of this lipoprotein into the extracellular space
and its diffusion between cells. Secretion requires the
sterolsensitive 12transmembrane protein Dispatched
[72]. In the extracellular space monomeric forms of Hh,
due to their hydrophobic properties, remain bound to the
outer side of the membrane and the extracellular matrix
[73]. However, Hh must diffuse over long distances to
play the role of the morphogen (a secreted protein, syn
thesized in a specific zone of a developing tissue and dif
fusing to form a concentration gradient so that the cellu
lar responses to the received signal depend on the local
concentration of the morphogen [74]). It is assumed that
this is achieved through special packaging of Hh into par
ticles that mask its lipid parts and have high diffusion
capacity. Such particles may be, for example, multimer
ized Hh aggregates [75] or lipoprotein particles [76]. It is
shown that an important role in packaging Hh in such
particles is played by the major protein of lipid rafts reg
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gie/flotillin [77]. Segregation of Hh into lipid rafts is
observed in Hhsecreting cells and depends on choles
terol modification of this morphogen [78].
Regardless of the molecular form in which Hh is
delivered to the signal recipient cell, Hh binds on its sur
face to the 12transmembrane protein Patched (Ptc); this
interaction is stimulated by coreceptors Ihog and Boi
[7981]. The Ptc receptor constitutively suppresses the
activity of another transmembrane protein Smoothened
(Smo) [82]. It is assumed that Ptc, as a homolog of sever
al transporter proteins, transports a low molecular weight
inhibitor of Smo [83]. Binding of Hh to Ptc inhibits this
transport activity, allowing Smo to signal to cytosolic
components of this cascade (Fig. 6). Smo is a G protein
coupled receptor (GPCR) by its topology and biochemi
cal activity [82, 84] and is related to receptors of the
Frizzled family (see below). However, the role of Gpro
teins in signal transduction by Smo remains unclear.
The key role in the Hhdependent signaling cascade
is played by a cytosolic complex of proteins organized by
the microtubule binding motor protein Costal2 [85, 86]
(Fig. 6). This complex also includes the kinases Fused,
PKA, CK1, and GSK3β, as well as the transcription fac
tor Cibitus interruptus (Ci) [87]. The function of this
cytosolic complex is sequential phosphorylation of Ci,
which leads to its recognition by the Fboxcontaining
ubiquitin ligase Slimb. Subsequent ubiquitination of the
Cterminus of Ci leads to its cleavage by proteasomes. The
remaining fragment of Ci (CiR) is released and enters the
nucleus, where it plays the role of a transcription repressor
[87, 88]. Active Smo reorganizes the cytosolic complex,
preventing phosphorylation and cleavage of Ci. As a
result, fulllength Ci (CiA) is translocated into the nucle
us and serves as an activator of transcription of target genes
of the Hhdependent signaling pathway [87].
Hedgehogdependent signal transduction and human
diseases. As in the case of the Notchdependent signaling
cascade, mutational underactivation of the Hhsignaling
pathway underlies a number of genetic diseases – human
developmental deficits, whereas mutational hyperactiva
tion of this cascade is responsible for hereditary predispo
sition to cancer or spontaneous forms of carcinogenesis
[89, 90]. For example, a heterozygous mutation in the
gene Sonic Hedgehog (Shh, the human Hh homolog)
causes holoprosencephaly – malformation of the brain
and face with varying degrees of manifestation, from
lethal cyclopia to milder facial defects [91, 92].
Holoprosencephaly occurs with a frequency of 48 cases
per 100,000 births. Interestingly, in rare cases, this defect
is caused by a heterozygous mutation in the gene Ptc,
which is supposed to be a gainoffunctionmutation and
thus also lowers the level of Hhdependent signal trans
duction [93]. In addition, approximately 5% of patients
with Smith–Lemli–Opitz syndrome (SLOS) also have
holoprosencephaly. Other symptoms of SLOS are micro
cephaly, growth retardation, mental retardation, etc.
SLOS is an autosomal recessive disease caused by a muta
tion in the gene for 7dehydrocholesterolreductase – the
enzyme responsible for a step in cholesterol biosynthesis.
It is assumed that this mutation also reduces the effec
tiveness of the Hhdependent signaling cascade [89, 90].
It is appropriate to note that hereditary holoprosen
cephaly and cyclopia are observed in lambs whose moth
ers ate the leaves of the corn lily (Veratrum) during preg
nancy [94]. The active substance responsible for these
defects was isolated from the corn lily in the 1960s; it was
called cyclopamine and found to physically bind Smo and
block its activity [95, 96]. Thus, mutational and pharma
cological reduction of activity of the Hhdependent sig
naling cascade at the later stages of embryo development
causes holoprosencephaly.
Greig cephalopolysyndactyly, Pallister–Hall syn
drome, type 3 postaxial polydactyly, and VACTERL syn
drome can be named among other pathologies caused by
mutational decrease of the Hhdependent signaling path
way activity. All these defects are caused by mutations
(hereditary or sporadic) in the genes of Gli3 and Gli2
(Drosophila homologs of the transcription factor Ci) [89,
90].
Hereditary or sporadic mutations that increase the
activity of the Hhsignaling pathway contribute to car
Fig. 6. The Hedgehogdependent signaling cascade. Hedgehog
synthesizing cell (left): 1, 2) the precursor protein undergoes auto
proteolysis with addition of a cholesterol residue to the Ctermi
nus and palmitoylation at the Nterminus by the acyltransferase
Skinny Hedgehog in the Golgi apparatus; 3) release of the lipidat
ed Hedgehog requires activity of the sterolsensing transmem
brane protein Dispatched; 4, 5) a lipid raft protein reggie/flotillin
(4), ensuring packaging of Hedgehog into lipoprotein particles
(5), is required for longrange diffusion of Hedgehog. On the
receiving cell (center), Hedgehog binds the receptor Patched (Ptc)
and coreceptors Ihog and Boi (6), which releases the active
GPCR Smoothened (Smo), which in turn provides stabilization of
the transcription factor Ci; Ci translocates to the nucleus and trig
gers transcription of target genes. In the cell, which has not
received the Hedgehog signal (right), Ptc acts as a transporter of a
low molecular weight inhibitor of Smo. In the absence of Smo
activity, a complex of proteins Costal2, Fused, PKA, CK1,
GSK3β forms in the cytoplasm (7) phosphorylating Ci, which
leads to its recognition by the ubiquitin ligase Slimb (8) and pro
teasomal cleavage of the Cterminus of Ci (9). The remaining
CiRfragment enters the nucleus where it plays the role of a tran
scriptional repressor.
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cinogenesis. About 40% of patients with Gorlin syndrome
have inactivating mutations in the gene Ptc (recall that
homozygous inactivation of this gene is lethal in early
embryogenesis). Since Ptc inhibits Smo and the whole
intracellular cascade, decrease of its amount contributes
to ligandindependent activation of this signaling path
way. Patients with Gorlin syndrome have a number of
developmental defects of the skeleton, such as polydacty
ly, overgrowth, fused ribs, and a high frequency of early
cancers, such as basal cell carcinoma and medulloblas
toma [89, 90, 97]. In addition, most of sporadic cases of
medulloblastoma, and virtually all cases of basal cell car
cinoma are associated with mutations in the gene Ptc [98,
99]. Other forms of cancer, such as cancer of the prostate,
breast, pancreas, liver, etc., are also frequently associated
with somatic mutations that lead to abnormal activation
of Hhdependent signaling cascade – a decrease in activ
ity of Ptc, the overproduction of Shh, or mutations in
other genes of that signaling pathway [98, 99].
Involvement of the Hedgehogcascade in early eye
development and progression of MF. Hh plays an impor
tant role in initiation of morphogenetic furrow (MF) and
in its progression [100] (Fig. 2). Hh is synthesized by cells
at the posterior pole of the eyeantennal disc, and its dif
fusion in the anterior direction contributes to the emer
gence of MF in this point [101]. Furthermore, ectopic
expression of Hh causes formation of additional MFs in
the early disc [101]. Progression of MF in the anterior
direction is provided by the launch of production of Hh
by cells differentiating into photoreceptors [102, 103].
One of the Hh target genes in the process of MF progres
sion is another secreted protein Dpp (see below), which
also regulates the progression of MF [102]. Another gene
whose expression is stimulated by Hh is atonal, which
triggers neuronal differentiation, the regulation of which
by the Notchcascade is described in the previous section
[104]. It is important to note that only undifferentiated
cells, located anterior to MF, are competent to respond to
the Hh signal. This is achieved though degradation of the
key Hh signal transducer, the transcription factor Ci, by
the action of the Cullin3containing protein complex in
the tissue through which MF has already passed, making
it unresponsive to Hh [100, 105]. Thus, reiterative pro
duction of the Hhmorphogen is achieved at the peak of
MF advancing in the anterior direction.
Dpp AND TGFβDEPENDENT
SIGNAL TRANSDUCTION
The ligand Decapentaplegic (Dpp) is a member of
the TGFβ (transforming growth factor β) superfamily of
protein signaling molecules and is the Drosophila
homolog of vertebrate ligands BMP2 (bone morphogenic
protein 2) and BMP4. All ligands of the TGFβ superfam
ily act as dimers [106] through receptor serine/threonine
kinases with a single transmembrane domain and a cyto
plasmic protein kinase domain (Fig. 7). These receptors
function as a heterotetramer formed by the binding of the
ligand, consisting of two copies of the receptor type I and
two copies of the receptor type II [107, 108]. Drosophila
receptor of the first type for Dpp is Thick veins [109, 110]
and of the second type – Punt [111, 112]. Constitutively
active receptor type II kinase phosphorylates the receptor
type I, activating it. This, in turn, leads to phosphoryla
tion of the cytoplasmic RSmadprotein: Mothers against
Dpp (Mad) in Drosophila [113], which makes it compe
tent to bind the coSmadprotein (Medea in Drosophila
[114116]). The heteromeric Smadcomplex translocates
into the nucleus, where it regulates transcription of target
genes.
Links between Dpp/Smaddependent signaling and
human diseases. Mutations in components of the Smad
signaling pathway are the basis of a number of hereditary
malformations [117]. For example, the heterozygous
genotype for a mutation in the TGFβreceptor 2
(TGFBR2) is responsible for 10% of cases of Marfan syn
drome – a systemic connective tissue disorder, which
manifests itself in childhood and is accompanied by dis
proportional growth, arachnodactyly, lens dislocation,
and complications of the cardiovascular system: mitral
valve prolapse and aortic dissection [117, 118]. Mutations
in TGFBR1 are also described in Marfan syndrome. In
80% of cases, this hereditary disorder is due to mutations
in the gene encoding fibrillin – the main component of
the extracellular matrix. It is assumed that the mutation
indirectly leads to increased activity of the TGFβ/Smad
Fig. 7. The Dppdependent signaling cascade. Binding of the
dimeric Dppligand (3) by the receptor Thick veins (1) and Punt
(2) causes their heterotetramerization. The constitutive kinase
activity of Punt leads to phosphorylation and activation of Thick
veins (4), which is responsible for phosphorylation of the RSmad
protein Mothers against Dpp (Mad, 5). Phosphorylated Mad
forms a complex with the coSmad protein Medea (6) and is trans
ported into the nucleus to trigger transcription of target genes.
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signaling cascade. Marfan syndrome clinically overlaps
with Loeys–Dietz syndrome, which is also caused by
haploinsufficiency in the TGFBR1 gene. It is curious that
in the case of TGFβreceptor mutations in Marfan and
Loeys–Dietz syndromes, histological analysis also shows
an increase in Smad phosphorylation, suggesting a para
doxical hyperactivation of the TGFβ/Smadsignaling
cascade in these tissues. Moreover, a partial recovery of
the phenotypes can be achieved in a mouse model of
Marfan syndrome by artificial lowering of TGFβ levels
[119]. Thus, congenital defects in Marfan and
Loeys–Dietz syndromes seem to be associated with
excessive levels of activation of the TGFβ/Smadsignal
ing cascade [117, 118]. Among other hereditary malfor
mations associated with mutations (typically haploinsuf
ficiency) in the gene components of this signaling path
way are hereditary hemorrhagic telangiectasia, thoracic
aortic aneurysm type A, Camurati–Engelmann disease,
and others [117].
The TGFβ/Smadsignaling pathway plays a dual role
in the development of cancer [120]. On one hand, this
type of intracellular signaling has the tumorsuppressive
function in early stages of carcinogenesis, and mutations
with reduced activity of this cascade are described in a
number of carcinomas [120]. For example, inactivating
mutations and deletions in the gene Smad4 are found in
half of all cases of pancreatic cancer [121]. TGFβ has
even been tested as an adjuvant for anticancer
chemotherapy in preclinical models [122]. The tumor
suppressive effect of the TGFβ/Smadsignaling pathway
is mediated by its ability to limit cell proliferation through
the launch of expression of cyclindependent kinase
inhibitors, such as INK4B and WAF1 [123, 124], as well
as by suppression of expression of cMyc [125]. In addi
tion, TGFβ is able to stimulate apoptosis by a not yet fully
studied mechanism [120, 126].
But on the other hand, TGFβ promotes metastasis at
later stages of cancer development, for example in cases
of breast, colon, and prostate cancer [120, 127]. One of
the ways TGFβ influences metastasis is its ability to stim
ulate epithelial–mesenchymal transition [128]. Thus,
both reduced and increased activity of the TGFβ/Smad
signaling pathway can lead to pathologies in organism
development and malignant transformation.
Participation of the Dpp/Smadsignaling pathway in
the early eye development. As mentioned above, dpp is
one of the Hh target genes in the origin and progression
of MF [102] (Fig. 2). As in the case of development of
Drosophila wings [129], Hh, being a poorly diffusing
morphogen, induces expression of the highly diffusive
morphogen Dpp, which plays a significant role in eye
morphogenesis [100]. The Dpp/Smadsignaling pathway
suppresses expression of the transcription factor
Homothorax (Hth) anterior to MF [130]. This allows
cells to enter into the proneural state and makes them
competent to respond to the incoming Hhsignal by the
time MF approaches them. In addition, Dpp inhibits
expression of another transcription factor hairy in the
region directly in front of MF [131], which in turn is nec
essary for removal of the transcriptional repression of
atonal – a key regulator of neuronal cell differentiation
(see above). The Hh and Dpp morphogens play partially
redundant roles in MF progression [102, 131, 132], for
example in regulation of expression of the Notchligand
Delta [56].
Wnt/Wingless: THE CANONICAL
SIGNALING CASCADE
Wntligands represent a family of secreted lipoglyco
proteins, playing key roles in organism development from
sponges to humans [133]. The human genome encodes 19
members of this family, and that of Drosophila – seven
(see http://www.stanford.edu/~rnusse/wntwindow.html).
The name Wnt reflects the history of discovery of these
proteins: the first Drosophila Wnt (Wingless, Wg) was
cloned as one of the segment polarity genes [134] almost
simultaneously with the homologous mammalian gene,
identified as the integration site int1 of the mouse mam
mary tumor virus [135]. During embryogenesis, Wntpro
teins function as morphogens: they are synthesized by a
specific region of a developing tissue and diffuse forming
a concentration gradient which is “read” by the other
cells; the cellular responses then depend on the local
morphogen concentration [74]. Thus it is not surprising
that the processes of secretion and diffusion of Wntlig
ands are tightly regulated [136, 137]. Wntsynthesizing
cells provide a number of posttranslational modifications
to the Wntprotein before it is released into the extracel
lular space (Fig. 8). Wnts undergo Nglycosylation at
multiple sites (asparagines 108 and 414 in Drosophila Wg)
by the action of the ERlocalized oligosaccharide trans
ferase complex [138]. The function of Nglycosylation
may be the regulation of apical secretion of Wntproteins
by epithelial cells [136, 137]. Biologically active Wnt also
has lipid modifications: palmitoylation of the conserva
tive cysteine residue, which lies in the first third of the
protein (cysteine 93 in Wg), also occurs in the ER by the
Oacetyltransferase Porcupine [139, 140]. A mutation in
the gene porc leads to accumulation of Wnt in the ER and
completely prevents the secretion of the morphogen [140,
141]. Additional modification by palmitoleic acid occurs
on the conservative serine residue (serine 209 in Wnt3a),
but it is unclear whether Porc or another acyltransferase is
responsible for it [142].
A specialized transmembrane protein Wntless/Evi/
Sprinter plays an important role in the process of Wntlig
and secretion [143145]. In the absence of this protein,
cells of nematodes, fruit flies, and mammals are unable to
secrete Wntligands to the extracellular space. Wntless
delivers Wntproteins from the Golgi to the plasma mem
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brane. For the ongoing secretion of new Wnt molecules,
maturing in the ER and the Golgi apparatus, Wntless
must be returned back to the Golgi. An important role in
this recycling of Wntless is played by the socalled
retromer complex of proteins; in its absence Wntless
accumulates at the plasma membrane and secretion of
Wnt is blocked [146149].
Similarly to the abovedescribed Hhmorphogen,
the lipid modifications make Wntligands hydrophobic
and in a monomeric form poorly diffusive through the tis
sue due to their high affinity to the outer side of the mem
brane and to the extracellular matrix [139, 150]. Thus,
both Wnt and Hh face the problem of the longrange
delivery, which is necessary for them to function as mor
phogens. Similarly to Hh, Wnt can package and diffuse in
lipoprotein particles to solve this problem [76].
Furthermore, we have identified the special role of reg
gieflotillin in the Wntproducing cells, directing Wnt
secretion into the pathway permitting such packaging
[77]. As we show below, the parallels between the Wnt
and Hhdependent signaling pathways are not limited to
the details of secretion and diffusion of these mor
phogens.
On cell surface, Wntligands bind to two types of co
receptors: 1transmembrane LRP5/6 (Arrow in
Drosophila) and 7transmembrane Frizzled (Fz) (Fig. 8).
Fz is related to Smo, which transmits the signal in the
Hhdependent pathway, and like Smo is a G proteincou
pled receptor (GPCR) [151153]. GPCRs represent the
largest family of receptors in animals and utilize het
erotrimeric Gproteins, consisting of the GDP/GTP
binding Gαsubunit and the Gβγheterodimer, as the
immediate cytoplasmic signal transmitters [154]. In the
inactive state Gα is associated with GDP and Gβγ.
Activated GPCR acts as a GEF (guanine nucleotide
exchange factor) to catalyze replacement of GDP to
GTP. This leads to dissociation of the heterotrimeric
complex into GαGTP and Gβγ, each of which is able to
activate downstream effector proteins [155]. Fzreceptors
primarily bind to and activate heterotrimeric Gproteins
of the Gi/o type both in Drosophila and in mammalian
cells [153, 156, 157]. Another important signal transmit
ter from Fz is the cytoplasmic protein Dishevelled (Dsh)
[158]. Dsh binds to the Cterminus of Fz [159], while the
heterotrimeric Gproteins usually interact with the intra
cellular loops of GPCR [160]. It remains unclear whether
the simultaneous interaction of Fzreceptor with both
types of intracellular transmitters is possible. It should be
noted however that in a number of genetic experiments
Dsh acts downstream from heterotrimeric Gproteins in
Fz signal transduction [156, 161]. A possible explanation
for this phenomenon has been provided by studies
demonstrating the physical interaction of Dsh with Gβγ
[162164]. Gβγ, released along with the Gαsubunit of
the initially trimeric Gprotein by the GEF activity of Fz
receptors, remains associated with the plasma membrane
through its lipid modifications [165] and recruits Dsh
from the cytoplasm, allowing it to interact with Fz [163].
The intermediate outcome of action of these intra
cellular signal transmitters is restructuring of the so
called destruction protein complex, which includes Axin,
APC, casein kinase (CK), and glycogen synthase kinase
3β (GSK3β) [166]. The function of this complex is bind
ing and sequential phosphorylation of cytoplasmic β
catenin, which leads to its ubiquitination and subsequent
proteasomal degradation [167] (Fig. 8). It is appropriate
to note another similarity with the Hhdependent signal
ing pathway, up to the involvement of the same kinase
(GSK3β) both in the Hhdependent complex, cleaving
Ci, and in the Wntdependent complex, degrading β
catenin.
The key role in reorganization of the destruction
complex triggered by Wnt is played by interaction of Axin,
organizer of this complex, with the receptor LRP5/6 and
intracellular signal transmitters Dsh and the Gαsubunit
of the heterotrimeric Go protein. These interactions dis
place other components of the complex. Axin is a protein
Fig. 8. Wnt/Frizzled: the canonical signaling cascade. In the Wnt
synthesizing cells (left), the Wntligand undergoes several post
translational modifications in the endoplasmic reticulum: Ngly
cosylation by the oligosaccharyltransferase complex (1), palmitoy
lation by the Oacyltransferase Porcupine (2), and additional
modification by palmitoleic acid (3). The Wntless protein plays a
key role in transportation of Wnt from Golgi to the plasma mem
brane (4). Wntligands can be packed into lipoprotein particles
(6); an important role in this process is played by the protein com
ponent of lipid rafts reggieflotillin (5). In the Wntresponding cell
(right), Wnt binds to the GPCR Frizzled (7) and 1transmem
brane receptor LRP5/6 (8). The key intracellular signal transmit
ters are heterotrimeric Gproteins (9) and Dishevelled (10). In the
absence of their activity, Axin (11) organizes a complex of pro
teins, which binds βcatenin (12) leading to its phosphorylation
(13) and proteasomal degradation (14). Under the influence of
Gαsubunits of heterotrimeric Gproteins, Dishevelled and
LRP5/6, Axin is relocated to the membrane (15) and displaced
from the destruction complex (16). As a result βcatenin accumu
lates and translocates into the nucleus (17) to activate transcrip
tion in coordination with LEF/TCF.
1568 KATANAEV, KRYUCHKOV
BIOCHEMISTRY  (Moscow)   Vol.  76   No.  13   2011
with multiple defined domains and a number of disor
dered regions, providing a platform for binding multiple
partners [168, 169]. So, Gαo is able to physically interact
with the RGSdomain of Axin [163], probably inhibiting
the binding of APC, which is a component of the destruc
tion complex [170]. On the other hand, Dsh binds to the
DIXdomain located on the opposite side of Axin [171].
Thanks to the combined action of Dsh and Gαo, Axin is
transferred to the membrane [163, 172], where it finally
starts to interact with the cytoplasmic tail of LRP5/6
[173]. This interaction is stimulated by phosphorylation of
LRP5/6 by CK and GSK3β [174, 175]. As a result of these
coordinated actions, Axindependent destruction com
plex is rearranged and becomes unable to bind and phos
phorylate βcatenin. As a result, the latter gradually accu
mulates in the cytoplasm and diffuses into the nucleus,
where it interacts with a number of transcriptional cofac
tors, first of all LEF/TCF, to induce transcription of target
genes of the Wntdependent signaling pathway [176].
Endocytosis plays an important role in the Wntcas
cade. Unlike the majority of GPCRs, internalization of
which leads to termination of intracellular signaling,
internalization of Fzreceptor serves to amplify the signal
[177]. An important role in the process of signal amplifi
cation is played by the small GTPase Rab5, the central
regulator of early stages of endocytosis [177, 178]. This
Gprotein is recruited by the Gαsubunit of the het
erotrimeric protein Go from the cytoplasm to the plasma
membrane, where its GEFregulators are localized [178].
Once in proximity to Fzreceptors, Rab5 stimulates their
internalization into early endosomes. Through an as yet
not fully understood mechanism, in this compartment the
Fzreceptor (or rather the WntFzLRP5/6 complex)
produces a greater impact on reorganization of the Axin
dependent destruction complex. It is possible that differ
ent components of Wntdependent signal transduction
are involved differently in transmission of the signal from
the plasma membrane versus the early endosomes [153,
178]. This mechanism can be used by cells for differential
responses to different concentrations of the Wntligand,
or to different ways of its packaging and presentation
[153].
The Wntdependent signaling pathway and human
pathology. Because the Wntdependent signaling pathway
plays an important role in organism development, it is not
surprising that mutations in genes encoding components
of this cascade are the basis for a number of hereditary
diseases and developmental malformations [179]. For
example, mutations in LRP5 are responsible for defects
in development of skeletal mass in humans: activating
mutations lead to excessive skeletal mass and inactivat
ing – to a decreased bone mass and osteoporosis [180
182]. Dominant mutations in the gene Fz4 are responsi
ble for development of familial exudative vitreoretinopa
thy – a vascular disease of the retina, accompanied by
peripheral vitreous opacities and retinal exudates in the
retina [183]. The reason for the dominance of this muta
tion is production of a truncated Fz4, which oligomerizes
with the normal receptor and retains it in the ER [184].
There are a number of other hereditary diseases associat
ed with malfunctioning of the Wntcascade [179].
In the adult organism Wntcascade is mostly off.
However, both underactivation and excessive activation
of this signaling pathway, e.g. due to somatic mutations,
lead to pathologies. Excessive activation of the Wntpath
way in a number of tissues contributes to carcinogenesis
[185]. About 50% of all breast cancer cases are associated
with aberrant activation of the Wntcascade, for example
due to overproduction of Wntligands or loss of produc
tion of natural Wntantagonists such as Dickkopf and
sFRP (secreted frizzledrelated protein) [186]. Mutations
in the genes APC and Axin are the basis for colon cancer:
more than 90% of all cases of this disease are associated
with such mutations [187]. Other tissues are also not
insured from carcinogenesis resulting from somatic
hyperactivation of this cascade: mutations in its compo
nents are described in many cases of stomach, ovarian,
prostate, and other cancers [187].
On the other hand, the proliferative function of the
Wntdependent signaling pathway defines the role of acti
vation of this cascade in regeneration of various tissues
after injury, and lack of activation of this pathway is sup
posed to prevent the full restoration of mammalian tissues
[188]. Therapeutic approaches to stimulate regeneration
are based on direct stimulation of this cascade, for exam
ple in case of bone repair after fractures [189]. However,
excessive Wntdependent proliferation can also cause
pathologies, distinct from carcinogenesis described
above. For example, excessive Wntdependent prolifera
tion of vascular smooth muscle cells can lead to thicken
ing of arterial walls and clogging of blood vessels;
increased activity of this cascade is also responsible for
cardiac hypertrophy [190].
Finally, the Wntsignaling pathway is important in
neuronal remodeling [191], and deficiency in the Wnt
cascade activation in neurons is associated with develop
ment of neurodegenerative diseases such as Alzheimer’s
disease [192]. It has been shown that the βamyloid pep
tide is able to physically bind Fz receptors and prevent
activation of Wntdependent signal transduction [193]. In
addition, it has been shown that directed activation of the
Wnt pathway has neuroprotective effects in cultured neu
ronal cells treated with βamyloids [194, 195].
Thus, the right balance between insufficient and
excessive levels of activity of the Wntdependent signaling
pathway is important for normal functioning of tissues
[196]. Studies of molecular mechanisms of this cascade
can identify new components that can serve as targets for
directed activation or deactivation by low molecular
weight drugs [197]. The Wntcascade plays an important
role in eye development in Drosophila, which is an ideal
object to study this signaling mechanism.
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Wnt/Winglessdependent signal transduction in early
development of Drosophila eyes. Wg performs several
functions during development of the eyeantennal disc,
such as the supply of positional information for the disc
morphogenesis, stimulation of differentiation of head tis
sues, etc. [198]. In the first larval instar, Wg acts in the
dorsal part of the eyeantennal disc [199] promoting
expression of homeodomain genes of the Iroquois com
plex, in particular mirror [200]. These genes suppress
dorsal expression of Fringe, the glycosyltransferase of the
Notchreceptor [5153]. As described in section “The
NotchPathway in Early Stages of Eye Development” of
chapter “The NotchSignaling Cascade”, exclusive
expression of Fringe in the ventral part of the disc plays an
important role in specification of the equator and the
choice of the point of initiation of the morphogenetic fur
row (MF).
In the second larval instar, Wg is present throughout
the disc, whereas in the third larval instar the zone of Wg
expression is limited to lateral margins of the eye part of
the disc [201, 202]. Wgdependent signal transduction
contributes to formation of the head capsule at the
expense of the eye cells: directed activation of the Wg cas
cade leads to transformation of the eye tissue into the
head cuticle, whereas mutational suppression of this sig
naling pathway leads to an increase in the eye size [203,
204]. The gradient of Wg, decreasing towards the equator,
prevents incorrect initiation of MF (Fig. 2) [205, 206].
The Wgcascade control over cell differentiation into the
head capsule at the expense of the eye tissue is determined
by regulation of MF formation: lowering Wg activity
transforms head capsule into the ectopic eye tissue due to
initiation of ectopic MF. In contrast, mutational activa
tion of the Wgcascade inhibits initiation of the normal
MF, blocking differentiation of the eye; eye disc cells
form excessive cuticular tissue of the head in this case
[203206].
The role of the Winglesscascade in formation of
peripheral structures of the eye. Normal ommatidia of
Drosophila eyes are separated from the cuticle of the head
capsule by a number of specific structures. On the border
with the head capsule, the eye is surrounded by the “pig
ment rim” (PR) – a narrow stripe of tissue consisting
entirely of pigmented cells that insulate the eye from side
wise illumination [9]. In addition, the socalled “dorsal
rim” (DR) lies on the dorsal side behind PR. DR is a row
of ommatidia specialized for polarized light detection due
to the particularly large central rhabdomeres of the R7
and R8 cells, both of which express the UVsensitive
opsin3 (see introductory section “Structure and
Function of the Drosophila Eye”); DR ommatidia also
have unusual neuronal projections to the optic ganglion
[9, 207]. Wg secreted by the head capsule plays the key
role in formation of both PR and DR [9, 208]. PR is
formed at the pupal stage as a result of apoptosis of non
pigment cells of ommatidia aligning the head capsule
[209]. In general, Wg can induce apoptosis of differenti
ated eye cells [9, 209211], and one of the earliest identi
fied alleles of wg, glazed, leads to eye reduction through
death of nonpigment cells induced by ectopic Wg
expression [212]. Additionally, ectopic Wg causes the
“mirror” eye phenotype due to loss of the antireflective
nanostructures of the corneal surface [2]. Formation of
DR requires synthesis of the transcription factor Hth
induced by Wg diffusing from the head capsule; lower
concentrations of Wg are required for DR as compared to
PR induction [9, 208].
Wingless diffusion sets the gradient of the “factor X”.
In addition to the described above functions of Wg in early
dorsal–ventral specification of the eye disc (see the sec
tion “Wnt/WinglessDependent Signal Transduction in
Early Development of Drosophila Eyes”), Wg plays an
important later role in formation of the equator and chi
rality of ommatidia. Diffusing deep into the eyes from
dorsal and ventral sides of the head capsule, Wg forms a
downward concentration gradient with a minimum at the
equator. Formation of a clone of cells ectopically synthe
sizing Wg can repolarize ommatidia in a non
autonomous way: ommatidia located on the polar side
(towards the head capsule) from Wgproducing cells
change their chirality and orientation in a mirrorreflec
tion and form an ectopic equator at the boundary with the
normallyoriented ommatidia [213, 214]. The effective
ness of such nonautonomous repolarization is the
stronger, the farther away from the head capsule the clone
localizes. Similarly, formation of a clone of cells that are
unable to transmit the signal from Wg, for example due to
loss of Wgcomponents of the cascade such as Arrow,
Dsh, or βcatenin, repolarizes ommatidia – but on the
equatorial side of the clone, the stronger the closer to the
poles (head capsule) clones localize [214]. On the basis of
these data a hypothesis has been formulated that the con
centration gradient of Wg from the pole to the equator
induces the counter gradient of “factor X” – secreted or
transmembrane substance(s), which determines activa
tion of Fzdependent “noncanonical” signaling cascade
that determines planar polarity of ommatidia [214, 215].
This signaling cascade is discussed in the next section.
THE NONCANONICAL
Frizzled/PCPSIGNALING CASCADE
In addition to the canonical, βcatenindependent
signaling cascade, which regulates transcription, Fz
receptors are capable of activating noncanonical signal
ing cascades [216]. The best studied among them is the
cascade that regulates planar cell polarity (PCP). The
Fz/PCPsignaling cascade directs “horizontal” polariza
tion of epithelial cells in the plane of the tissue, perpendi
cular to the “vertical” apicalbasolateral polarization of
epithelia. This depends on the proper polarization of the
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cytoskeleton and is independent from changes in the
transcriptional profile of cells [217]. PCP is manifested
morphologically, for example, by formation of actinrich
hairs by Drosophila wing cells; each hair grows in the dis
tal direction. In mammals, PCP manifests itself, for
example, in polarization of hair cell stereocilia in the
Corti organ of the inner ear. Cells participating in PCP
respond by polarization of their cytoskeleton to the extra
cellular polarizing information. In this sense, PCP is sim
ilar to chemotaxis of leukocytes and directed growth of
yeast cells stimulated by a pheromone [218, 219]. In all
these events, polarization of the cytoskeleton is triggered
by GPCRs, in the case of PCP – Fz [220].
However, the question of which ligand activates the
Fz/PCPsignaling cascade remains open. While in verte
brates involvement of “noncanonical” Wntligands such
as Wnt5a, Wnt11, and others in activation of PCP has
been demonstrated [221, 222], experiments in
Drosophila have revealed that neither Wg nor other Wnt
ligands represent the “factor X” – the mysterious activa
tor of the Fz/PCPsignaling pathway [223, 224]. Studies
of the role of proteins Fat, Dachsous, and Fourjointed in
the regulation of PCP were launched some years ago.
These proteins form gradients of expression and activity
in developing tissues and thus are wellsuited for the role
of “factor X” [225, 226]. However, genetic experiments in
Drosophila clearly demonstrated that Fz and
Fat/Dachsous organize independent signaling pathways
redundantly coordinating PCP [227].
How is the intracellular signal transduction in the
Fz/PCPsignaling cascade organized? Fzreceptors, ini
tially uniformly distributed in the apical plasma mem
brane, accumulate with the development of PCP on one
pole (distal in the case of Drosophila wing cells), deter
mining the future place of activation of the actin
cytoskeleton (and hair outgrowth in the wing cells) [228].
Apparently, proteins involved in PCP can be divided into
Fzsignal transmitters and signal amplifiers; mathemati
cal modeling of PCP also separates the Fz/PCPsignaling
cascade into two phases: receiving the transient polarizing
signal, and subsequent establishment of cell polarization
on the basis of massive relocalization of protein compo
nents of PCP [229]. Direct transmitters of the Fz/PCP
signal, as in the canonical Wntdependent pathway, are
apparently heterotrimeric Gproteins and Dsh [156,
230]. Proteins that play an important role in the subse
quent relocalization of Fzreceptors are Prickle, Van
Gogh, Diego, and a 7transmembrane protein Flamingo
[231235]. In addition, relocalization of Fz depends on
small Rabproteins that regulate vesicular transport,
namely Rab5 described above (see chapter
“Wnt/Wingless: the Canonical Signaling Cascade”) and
Rab11 regulating slow recycling of endosomes to the plas
ma membrane [178]. Apparently, Rab5dependent endo
cytosis is required for microtubule anchoring and trans
port of Fzcontaining endosomes in the distal direction
[178, 236, 237], while Rab11dependent recycling is
required for the release of Fz at the distal membrane
[178]. Finally, small Gproteins of the Rho family are
responsible for execution of the cell polarization response
program: actin growth of hairs on the wing of Drosophila
and rotation of ommatidia in the eye [238].
The Frizzled/PCPsignaling cascade and human
pathology. In vertebrates, PCP is involved in neural tube
closure [239]. Mutations in PCPcomponents in animal
models cause defects in this process of late embryogene
sis [217, 239]. In humans, mild defects in neural tube clo
sure occur in 12 infants per 1000, and in some cases are
associated with mutations in the gene Vangl1 (homolog of
Drosophila Van Gogh) [240]. The Fz/PCPsignaling cas
cade is also involved in carcinogenesis, but, in contrast to
the canonical βcatenindependent cascade that can
cause malignant transformation, Fz/PCP is involved in
later stages of cancer progression, such as invasiveness
and metastasis of cancer cells [241]. For example, Wnt5a
increases aggressiveness of metastatic gastric cancer and
melanoma, directly stimulating migration of cancer cells
[242, 243] – yet another parallel between the PCP and
chemotaxis [218].
The Frizzled/PCPsignaling cascade in regulation of
ommatidial polarity in Drosophila. A Drosophila omma
tidium in a crosssection forms an asymmetrical trape
zoid, where the photoreceptor rhabdomere R3 stands
aside from the rest of the rhabdomeres (Figs. 1 and 4).
Thus, ommatidia have chirality, which is the same for all
ommatidia in the dorsal half of the eye and is mirrored in
the ventral ommatidia. In addition, all ommatidia are ori
ented with their R3tops towards the poles of the eye (Fig.
4). Chirality and orientation of ommatidia is determined
by the level of activation of the Fz/PCPsignaling path
way in progenitor cells of photoreceptors R3 and R4. In
an ommatidial precluster, these cells initially occupy
symmetric positions on opposite sides of the precluster, so
that one of them is located closer to the equator, and the
other – closer to the pole of the eye [215]. As the con
centration of “factor X” is supposed to be at maximum at
the equator and to decrease towards the poles, the pro
genitor cell initially closest to the equator receives more
“factor X” signal [215]. At subsequent stages of precluster
development, R3/R4 precursor cells engage in a physical
contact with each other and “compare” their levels of
activation of the Fz/PCPcascade. This comparison is
achieved by the negative impact of Dsh on Notch [244]:
Dsh, activated by the Fz signaling pathway, physically
binds to the cytoplasmic domain of Notch and directs this
receptor to a degradation compartment [245]. As in
Drosophila wings, the Fz/PCPsignaling cascade in
R3/R4 cells leads to relocalization of components of the
cascade, so that the future R3cells accumulate Fz and
Dsh at the border with the future R4, while the latter
locates them on the opposite side, beyond the contact
zone with the neighbor cell [246, 247]. This also helps to
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selectively reduce the number of Notchreceptors in the
future R3 on its border with the R4. And next the much
discussed above process of lateral inhibition (see chapter
“The NotchSignaling Cascade”) is engaged again to
amplify the differences in activation of the Notchcas
cade between neighboring cells [215, 248, 249]. As a
result, the cell that had a greater level of activation of the
Fz/PCPpathway completely inhibits the Notchcas
cade, becomes the R3photoreceptor, and pulls itself
away from the tight ommatidial precluster. The second
cell becomes the R4.
THE RECEPTOR TYROSINE
KINASESIGNALING CASCADE
The human genome encodes 58 transmembrane
receptors with tyrosine kinase activity, distributed over 20
functional groups [250], including the family of epider
mal growth factor receptors (EGFR), the insulin receptor
family, the family of fibroblast growth factor receptors
(FGFR), etc. In most cases, receptor tyrosine kinases
(RTK) are monomers dimerizing upon binding of the lig
and. The Drosophila genome encodes only 15 RTKs.
However, studies on this model organism have played a
key role in the deciphering of the RTKsignaling cascade.
Therefore, we deviate from the standard structure of our
review and describe this cascade on the example of devel
opment of the R7photoreceptor in Drosophila and the
role of intracellular signaling initiated by the RTK
Sevenless in this process (Fig. 9).
The first human RTK, EGFR, was cloned in 1984.
Its amplification in cells of epidermoid carcinoma and its
homology to the verbB oncogene of avian erythroblasto
sis virus immediately pointed to the potential role of the
RTK in carcinogenesis (see below) [251]. Sevenless (Sev),
the first Drosophila RTK, was cloned in 1987 [252].
Initially, a mutation in the sev gene was obtained in the
laboratory of Seymour Benzer in a search for mutants
defective in phototaxis [253]: wildtype flies prefer UV
light in a Tmaze, while sev mutants lose this preference.
Subsequent work showed that the photoreceptor R7 bear
ing the UVsensitive opsin was absent in the mutant [254]
and was replaced by an additional cone cell [255]. The lig
and for Sev turned out to be the transmembrane protein
Bride of Sevenless (Boss), expressed by the R8photore
ceptor to activate the neighboring R7cell [256]. Further
experiments to search for mutations that could rescue the
sev phenotype laid the architecture of the RTKsignaling
cascade. Thus, the kinase activity of Sev and its ability to
autophosphorylate has been shown necessary for the for
mation of R7photoreceptors [257, 258]. Son of Sevenless
(Sos), which was identified as the guanine nucleotide
exchange factor for the small GTPase Ras1 [259261],
emerged as the key intracellular transmitter of the signal
from Sev. Moreover, the activated form of Ras1 was able to
rescue the loss of R7 in sev and boss mutants and also
induced formation of multiple R7cells [262].
The SH2/SH3 domaincontaining adapter protein
Downstream of Receptor Kinase (Drk/Grb2) plays a
central role in the activation of Sos and Ras1 by the active
(i.e. autophosphorylated) form of Sev. Drk/Grb2 binds
both to Sos and phosphorylated Sev (the latter through its
SH2domain) bridging the two proteins [263, 264]. While
guanine nucleotide exchange factors activate Gproteins,
GTPase activating proteins (GAP) perform the opposite
function accelerating the transition of Gproteins into
the inactive GDPbound state. Gap1 was isolated as a
negative regulator of Ras1 and the Sevdependent signal
ing cascade [265]. Finally, Raf, the first kinase of the
Fig. 9. The receptor tyrosine kinasesignaling cascade with
Sevenless as an example. Binding of the transmembrane ligand
Bride of Sevenless (Boss) to the receptor tyrosine kinase Sevenless
(Sev) leads to dimerization and autophosphorylation of the latter.
Phosphorylated Sev is recognized by the adapter protein
Drk/Grb2, which recruits the guanine nucleotide exchange factor
Son of Sevenless (Sos) from the cytoplasm. Sos activates the small
Gprotein Ras1 (the opposite action is played by Gap1). GTP
bound Ras1 activates the MAP kinase signaling cassette, consist
ing of the kinases Raf, Dsor1, and Rolled, successively phospho
rylating and activating each other. The active form of the MAP
kinase Rolled is translocated into the nucleus where it phosphory
lates transcriptional activators Pointed and Jun, as well as the
transcriptional suppressor Yan.
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MAP (mitogenactivated protein)kinase complex, was
identified as an essential component of the RTKcascade,
activated by Ras1 and capable upon constitutive activa
tion to promote the formation of R7cells even in the
absence of Sev [266]. The subsequent kinases of the
MAPkinase complex – MAPKK Dsor1 (Downstream of
raf1) [267] and MAPK Rolled [268] – are also necessary
for the specification of R7. Among targets of the MAP
kinase Rolled are nuclear transcription activator proteins
Jun [269] and Pointed [270], as well as the repressor Yan
[270]. Phosphorylation by the MAPkinase triggers tran
scription of several target genes, including the gene phyl
lopod [205], which together with another nuclear protein
Sina is needed for further steps of specification of the R7
photoreceptor [262, 271]. A number of additional regula
tors of the RTKsignaling pathway have been identified in
addition to the components described here [272].
Participation of RTK signaling pathways in human
diseases. Cloning of the first RTK (EGFR) revealed a
potentially important role of this type of signal transmis
sion in carcinogenesis [251]. A vast array of subsequent
studies has confirmed this role. There are two principal
ways of cancerous transformation due to hyperactivation
of RTK in human cells. The first is excessive production
of RTK by gene amplification, the second – activating
mutations in the RTK genes [273]. For example, the
genes of receptors EGFR and ErbB2 are often amplified
in lung carcinoma and breast cancer [273, 274]. In par
ticular, 30% of the breast cancer cases amplify the ErbB2
gene 220 times, and the level of ErbB2 overexpression
correlates with the aggressiveness of the tumor and
reduced patient survival [275]. Activating mutations in
EGFR have been described in human glioblastoma cells
[276]. Activating mutations in the RTK Ret underlie
hereditary cancer syndromes: multiple endocrine neopla
sia 2A and 2B, and familial medullary thyroid carcinoma
[273]. Many other cases of amplification and activating
mutations in the RTK genes, contributing to carcinogen
esis in different tissues, have been described [273, 274].
The active center of kinases is very convenient for
development of small molecule inhibitors, which are typ
ically based on ATP analogs (such convenience of target
proteins is called “druggable”). Thus pharmaceutical
companies are actively searching for anticancer drugs that
block the activity of various RTK. A significant number of
RTK inhibiting anticancer drugs are already on the mar
ket [273, 274, 277]. Here are some examples:
– Imatinib (Glivec) from Novartis inhibits among
other targets the RTK cKIT and is used in particular for
the treatment of cKITpositive stromal tumors of the
gastrointestinal tract [278];
– Iressa (Gefitinib) from AstraZeneca inhibits
EGFR and is used to treat nonsmall cell lung cancer
[279];
– Pazopanib (Votrient) from GlaxoSmithKline acts
among other targets on the RTK VEGFR (vascular
endothelial growth factor receptor) and is used to treat
advanced renal cell carcinoma [280];
– Lapatinib from GlaxoSmithKline acts on EGFR
and Erb2 and is used to treat Erb2overexpressing
metastatic breast cancer [281].
The RTKsignaling cascade in Drosophila photore
ceptor recruitment. We have described above the role of
signaling by the RTK Sev in formation of photoreceptor
R7. In the absence of this signal the R7precursor does
not choose the neural fate and instead becomes a cone
cell [255]. However, RTKdependent signal transduction
plays a more general role in neuronal differentiation in
the developing eye. Specifically, the RTK EGFR and its
secreted ligand Spitz are needed for sequential recruit
ment of photoreceptors R1R6 and then the remaining
ommatidial cells into the ommatidial precluster (see Fig.
3) [100]. Removal of EGFR or Spitz leads to formation of
dramatically reduced eyes containing only R8photore
ceptors, which are first to differentiate and are the only
cells not requiring activation of the RTKcascade for
their appearance [282, 283].
R8cells are the first to start synthesizing Spitz,
which stimulates neighboring cells for neuronal differen
tiation; these cells become photoreceptors R2 and R5.
The latter also begin to produce Spitz, which promotes
recruitment of R3 and R4, and then R1 and R6 (Fig. 3).
Artificial activation of EGFR can even compensate for
the absence of Sev in the R7 cell precursor [282].
Not only photoreceptors but also cone cells require
activation of the SpitzEGFR cascade for their differen
tiation [282]. Why, then, do cone cells not become pho
toreceptors of the R1/6 type? Because, unlike the R1/6
cells, cone cells also activate the Notchcascade through
contact with Deltaexpressing photoreceptors (Fig. 3)
[12]. But then why do cone cells not become R7pho
toreceptors, which, as described above, require both the
Notch and RTKsignal for their specification (the latter
through the BossSev interaction)? Because, in contrast
to the R7cells that receive high levels of the RTK activa
tion cascade, activation of this cascade in cone cells
achieved through the interaction of Spitz with EGFR is
much weaker [12].
In addition, an important role in cell differentiation
in the developing eye is played by Argos, an extracellular
inhibitor of EGFR [284], secreted by cells in response to
activation of the EGFRsignaling cascade [285] and hav
ing a higher diffusion capacity in comparison to Spitz
[286]. Based on these data a hypothesis has been formu
lated on the synthesis of a poorly diffusible activator and
a welldiffusing EGFR inhibitor, achieved in expanding
concentric waves around R8, capturing all the new cells
in a growing ommatidial cluster [282]. This model also
predicts the importance of the temporary component in
RTKstimulated differentiation: cells recruited earlier
become photoreceptors, the later ones become cone cells,
and even later – pigment cells [282].
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In addition to regulating differentiation, activation
of the RTKsignaling cascade through the Spitz–EGFR
ligand–receptor pair is important for preventing apopto
sis in the Drosophila eye cells, including secondary and
tertiary pigment cells [283, 287].
METHODS FOR STUDYING EYE
DEVELOPMENT IN DROSOPHILA
Numerous data described in previous sections were
based on welldeveloped histological, immunochemical,
and microscopic techniques of analysis of both eye
antennal larval discs and crosssections of adult fly eyes,
polished by many laboratories. However, not these neces
sary methodologies make the fruit fly such a convenient
object for studies, but the unique technologies of genetic
manipulation. Over a hundred years of radiation, chemi
cal, and Pelement mutagenesis in combination with the
compactness of the Drosophila genome have created a
huge collection of mutant lines that cover most of the
genes of this insect. The very development of these meth
ods has given a tremendous impetus to further investiga
tions and led to breakthrough discoveries of general bio
logical significance (see, e.g. [67]).
Many (and often the most interesting) mutations are
homozygous lethal; the lethality sometimes occurs too
early in embryogenesis to study the role of the correspon
ding genes in eye development. To circumvent this prob
lem, researchers have developed the FLP/FRTsystem to
produce somatic clones, homozygous mutant for the
desired gene [288, 289]. FRT (FLP recombinase recogni
tion target)sequences have been integrated in various
positions of Drosophila chromosomes. The investigated
mutant allele (e.g. an allele of the gene arrow, located at
the cytological position 50A950A11 of the right arm of
the second chromosome) is recombined with the FRT
sequence located proximally on the chromosome (for
example, FRT42D, located at the cytological position
42D of the same chromosome). Next, a marker gene (in
eye experiments it is often the gene white, encoding the
transporter of pigment for pigment cells and photorecep
tors) is integrated distally from the FRT (with the
endogenous copy of the white gene of the first chromo
some being mutated). Finally, the key gene in this exper
imental approach, the yeast flippase (FLP), is integrated
into the genome of Drosophila, for example, under the
control of the heat shock protein promoter (hsFLP). To
generate somatic clones, young larvae (e.g. of the age of
2448 h after egg laying) heterozygous for the mutation
under study are collected. In our example involving the
arrow gene, they would be of the following genotype:
white[–], hsFLP; FRT42D, arrow[2]/FRT42D, white[+].
Heat shock (1 h at 37°C) causes expression of flippase,
which stimulates sitespecific recombination between the
two FRTsites in dividing somatic cells. As a result the
heterozygous parent cell produces one daughter cell
homozygous mutant for arrow[2], and one homozygous
wildtype for arrow. Simultaneously, the first cell loses the
marker white[+]. Dividing, these cells form clones. The
clones identified in the whole eye and on histological
crosssections by the absence of pigment will be com
pletely devoid of the Arrow protein (the coreceptor for
Wg), which allows studying its role and the function of the
Wntdependent signaling cascade in general in eye devel
opment [9, 214]. It should be added that embryos
homozygous for mutant arrow[2] are defective in estab
lishment of segment polarity and die without even pro
ducing first instar larvae [290]. In addition to hsFLP
inducing expression of flippase everywhere under the
influence of a heat shock, one can use more tissuespecif
ic constructs such as EyFLP expressing flippase under
the control of regulatory sequences of the gene eyeless
[291].
A huge role in the development of Drosophila genet
ics was played by the technology of transgenesis – incor
poration of foreign genes into the genome of the insect.
This method uses the enzyme and sequences of transpos
able elements (Pelements) for the random integration of
the desired DNA into the genome [292]. Recently new
methods for directed integration into defined loci have
also been developed [293296].
Another technology that has tremendous value for
Drosophila genetics was also established on the basis of
the introduction of foreign yeast sequences into the insect
genome. It is the famous Gal4/UASexpression system
[297]. The desired gene (Drosophila or human, wildtype
or mutant) is cloned into a cassette containing the UAS
sequence (upstream activation sequence: an enhancer
element not recognizable by any Drosophila transcription
factors), and this cassette is integrated into the genome.
Crossing this UASX line with a line expressing the yeast
transcription factor Gal4 results in expression of the gene
X. Having a large collection of various Gal4lines,
researchers can achieve expression of the desired trans
gene in virtually any desired tissue and at any desired
stage of development. Here is a list of lines used in the
studies of eye development (for a more complete list see
http://f lystocks.bio. indiana.edu/Browse/misc
browse/gal4.htm; http://flybase.org/):
– GMRGal4: the construct contains five repetitive
elements of the gene promoter Rh1, interacting with the
transcription factor Glass; it causes expression in postmi
totic cells of the eye [282];
– EyGal4: contains an enhancer gene eyeless,
expression occurs in the early eye cells before MF [298];
– SevGal4: contains the enhancer of the gene
Sevenless; expression is observed in differentiating
photoreceptor cells, primarily R7, as well as cone cells
[299];
– LozengeGal4: leads to expression in cells of the
“R7equivalent group”: R7, R1/6 and cone cells [300];
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– CG7077Gal4: expression in pigment cells [301];
– Rh1Gal4 (ninaEGal4): expression in photore
ceptors R1R6 [302].
Finally, the combination of the Gal4UAS, high
throughput transgenesis, and RNA interference tech
nologies has led to creation of a collection of transgenic
fly lines carrying RNAiconstructs against most
Drosophila genes under the control of the UASenhancer
[303]. This collection (Vienna Drosophila RNAi Center,
VDRC: http://stockcenter.vdrc.at/control/main) is a
resource of tremendous value to researchers, as evidenced
by the fact that since its appearance, VDRC has delivered
more than six hundred thousand lines to different labora
tories throughout the world.
EXAMPLES OF USAGE
OF THE DROSOPHILA EYE AS A MODEL
FOR STUDYING HUMAN DISEASES
Alzheimer’s disease. In 2006 this disease affected
about 20 million people. The disease is characterized by
loss of neurons in the cerebral cortex and subcortical
areas. In 1991, the “amyloid hypothesis” was formulated,
according to which the underlying cause of the disease is
deposition of neurotoxic amyloid βpeptide [304].
Drosophila is of a considerable interest as a model organ
ism for studying Alzheimer’s disease due to a large degree
of homology and the interchangeability of human and
Drosophila proteins. Thus, γsecretase from flies proper
ly cleaves the precursor of the human βamyloid (APP).
To create a complete model one had to express (mostly
using the line GMRGal4) human APP and βsecretase
in Drosophila, which led to formation of βamyloid
plaques and agedependent neurodegeneration [305].
These phenotypes were restored by adding inhibitors of β
secretase and γsecretase in fly food, proving the useful
ness of this model in studying the mechanisms of the
pathogenesis of Alzheimer’s disease and in finding new
means of its treatment [305].
There are also simpler models of Alzheimer’s dis
ease, directly expressing the βamyloid peptide. Thus,
expression of the peptide Aβ42 in the Drosophila eye
under the control of GMRGal4 led to defects in eye
structure and neurodegeneration; the severity of the phe
notypes depended on expression levels and age [306,
307]. While Aβ42 forms stable aggregates in Drosophila
tissues, the Aβ40 peptide showed a lower stability and
caused no phenotypes [306, 307]. The effectiveness of
these models for drug discovery is shown by the example
of restoration of the Aβ42 phenotypes upon addition of
the βamyloid aggregation inhibitor Congo red to the fly
food [307].
Parkinson’s disease. The mechanism of this disease
is not fully understood, but it is characterized by accumu
lation of αsynuclein aggregates and loss of dopamine
neurons in the human central nervous system [308].
Expression of human αsynuclein in Drosophila neurons
(by elavGal4) and eye (by GMRGal4) led to accumula
tion of aggregates of the protein and neurodegeneration
increasing with age [309]. The Drosophila model of
Parkinson’s disease was used to demonstrate for the first
time the previously predicted relationship between α
synuclein phosphorylation and its ability to aggregate and
induce neurodegeneration. Indeed, phosphorylation of
αsynuclein on the site Ser129, previously observed in
brain tissue of patients with Parkinson’s disease, correlat
ed with its aggregation in Drosophila [310]. Moreover, a
nonphosphorylatable mutant form of αsynuclein
(S129A) did not cause neurodegeneration in Drosophila,
whereas the form S129D, simulating the constant phos
phorylation, increased neurotoxicity in comparison to the
wildtype form of αsynuclein [311].
Huntington’s disease. This disease is caused by mul
tiplication of the codon CAG (encoding glutamine) in the
gene for the 350kDa protein huntingtin [312]. Directed
expression of the Nterminal fragment of human hunt
ingtin with different numbers of glutamine repeats using
GMRGal4 caused degeneration of photoreceptors; both
the age at which degeneration began and its magnitude
depended on the length of repeats [313]. It was also
shown that proteins dTRP2 (homolog of the human
TRP2 (tetratricopeptide repeat protein2)) and dHDJ1
(homolog of human HSP40/HDJ1) significantly rescued
the phenotype, perhaps due to activation of the ATPase
activity of hsp70 [314]. This assumption was confirmed
by a study with directed expression of hsp70, which res
cued the eye phenotypes [315]. Numerous investigations
continue to study proteins genetically interacting with
huntingtin in the Drosophila model to shed light on the
mechanisms of Huntington’s disease and hopefully con
tribute to future development of drugs against it.
The HumanaFly project. One of the important
approaches to study cancer is to reproduce it in model
organisms, including Drosophila. Signaling pathways that
control differentiation, cell proliferation, and apoptosis
are similar in all multicellular animals, and proteins
involved in them are homologous and often interchange
able. As described in many examples above, disruption of
these signaling pathways in the human body often leads to
carcinogenesis. Knowledge about which gene causes
these disorders permits identifying ways of blocking its
activity, and therefore can be used to develop drugs. This
is the basis of our project HumanaFly (Kryuchkov,
Averkov, Khaustov, Katanaev, unpublished data). We use a
cDNA plasmid library, prepared from mRNA from
human breast cancer cells and cloned under the control
of UASenhancer, to introduce human genes into the
genome of Drosophila by highthroughput transgenesis.
Overexpression of the transgene occurs in the developing
eye of the insect using the GMRGal4 line. From numer
ous transgenes generated we select only those whose
EYE OF DROSOPHILA AS A MODEL TO STUDY PATHOGENESIS 1575
BIOCHEMISTRY  (Moscow)   Vol.  76   No.  13   2011
expression leads to disruption of eye development, and
operationally call them potential protooncogenes or
tumorsuppressors. We identify these genes through
sequencing. Analysis of morphology and histology of the
adult eye and eyeantennal disc provides an initial idea of
the mechanisms of developmental disorders caused by the
human transgene. Subsequent genetic experiments exam
ine the mechanism of pathogenesis and allow identifying
the Drosophila signaling pathways or cellular programs
that are affected by the human transgene. These studies
and confirmation of the collected data in mammalian
cells will help identify new protooncogenes and the
mechanisms of their effect in carcinogenesis. The project
HumanaFly represents the first largescale attempt of
using the developing Drosophila eye to study the effect of
human proteins (potentially pathogenic) in the paths of
intracellular signal transduction. The project is still in
early stages, but we have already identified three potential
new human protooncogenes, one of which unexpectedly
affects the Wnt/Frizzledsignaling cascade.
In this review we discussed pathways of intracellular
signal transduction that are active in animal development:
the Notch, Hedgehog, TGFβ, Wnt, PCP and the recep
tor tyrosine kinase pathways. Both insufficient activity
and overactivation of these signaling pathways underlies
many human diseases, especially cancer. Hopes for emer
gence of drugs against these diseases are associated with
creation of adequate models for studying the underlying
signaling cascades. The purpose of our review was to pro
vide the developing eye of the fruit fly Drosophila
melanogaster as such model. We have tried to describe in
detail the development of the visual organ of Drosophila
and the signaling pathways that regulate its various stages,
in the hope that this model will be utilized by molecular
and medical genetics looking for new approaches to study
human diseases. The abovementioned signaling path
ways are used repeatedly in insect eye development, and
defects (suppression of excessive activation) of any of
them lead to clear morphological consequences. The high
degree of homology and interchangeability of most pro
tein components of these cascades between humans and
Drosophila provide additional arguments for the utility of
this model. Finally, precise genetic and histological tech
niques permit sophisticated experimentation on the fruit
fly’s eye, impossible with other model organisms. All
these considerations argue for the active use of the devel
oping Drosophila eye model to study the mechanisms of
pathogenesis and for drug discovery. Indeed, a number of
successful examples of such use in the case of neurode
generative disease and cancer are mentioned in our arti
cle. We hope that future research will advance this success
and that the fruit fly, after a hundred years of use for
studying the fundamental laws of biology, will remain in
demand as the object of research, this time also medical
ly oriented.
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